Lack of Gα$_{i2}$ leads to dilative cardiomyopathy and increased mortality in β$_1$-adrenoceptor overexpressing mice

Kirsten Keller[1], Martina Maass[2], Sara Dizayee[1], Veronika Leiss[3], Suvi Annala[1], Jessica Köth[1], Wiebke K. Seemann[1], Jochen Müller-Ehmsen[4], Klaus Mohr[5], Bernd Nürnberg[3], Stefan Engelhardt[6], Stefan Herzig[1], Lutz Birnbaumer[7], and Jan Matthes[1]*

[1]Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany; [2]Department of Internal Medicine III, University Hospital of Cologne, Cologne, Germany; [3]Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, and Interfaculty Center of Pharmacogenomics and Drug Research, Tuebingen, Germany; [4]Asklepios Klinik Altona, Hamburg, Germany; [5]Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn, Bonn, Germany; [6]Institute of Pharmacology and Toxicology, Technische Universität München, Munich, Germany; and [7]Laboratory of Neurobiology, NIEHS, NIH (Department of Health and Human Services), Durham, USA

Aims	Inhibitory G (G$_i$) proteins have been proposed to be cardioprotective. We investigated effects of Gα$_{i2}$ knockout on cardiac function and survival in a murine heart failure model of cardiac β$_1$-adrenoceptor overexpression.
Methods and results	β$_1$-transgenic mice lacking Gα$_{i2}$ (β$_1$-tg/Gα$_{i2}^{-/-}$) were compared with wild-type mice and littermates either overexpressing cardiac β$_1$-adrenoceptors (β$_1$-tg) or lacking Gα$_{i2}$ (Gα$_{i2}^{-/-}$). At 300 days, mortality of mice only lacking Gα$_{i2}$ was already higher compared with wild-type or β$_1$-tg, but similar to β$_1$-tg/Gα$_{i2}^{-/-}$, mice. Beyond 300 days, mortality of β$_1$-tg/Gα$_{i2}^{-/-}$ mice was enhanced compared with all other genotypes (mean survival time: 363 ± 21 days). At 300 days of age, echocardiography revealed similar cardiac function of wild-type, β$_1$-tg, and Gα$_{i2}^{-/-}$ mice, but significant impairment for β$_1$-tg/Gα$_{i2}^{-/-}$ mice (e.g. ejection fraction 14 ± 2 vs. 40 ± 4% in wild-type mice). Significantly increased ventricle-to-body weight ratio (0.71 ± 0.06 vs. 0.48 ± 0.02% in wild-type mice), left ventricular size (length 0.82 ± 0.04 vs. 0.66 ± 0.03 cm in wild types), and atrial natriuretic peptide and brain natriuretic peptide expression (mRNA: 2819 and 495% of wild-type mice, respectively) indicated hypertrophy. Gα$_{i3}$ was significantly up-regulated in Gα$_{i2}$ knockout mice (protein compared with wild type: 340 ± 90% in Gα$_{i2}^{-/-}$ and 394 ± 80% in β$_1$-tg/Gα$_{i2}^{-/-}$, respectively).
Conclusions	Gα$_{i2}$ deficiency combined with cardiac β$_1$-adrenoceptor overexpression strongly impaired survival and cardiac function. At 300 days of age, β$_1$-adrenoceptor overexpression alone had not induced cardiac hypertrophy or dysfunction while there was overt cardiomyopathy in mice additionally lacking Gα$_{i2}$. We propose an enhanced effect of increased β$_1$-adrenergic drive by the lack of protection via Gα$_{i2}$. Gα$_{i3}$ up-regulation was not sufficient to compensate for Gα$_{i2}$ deficiency, suggesting an isoform-specific or a concentration-dependent mechanism.
Keywords	Adrenergic receptor • Inhibitory G protein • Cardiomyopathy • Heart failure • Cardioprotection

1. Introduction

Norepinephrine concentrations and sympathetic drive are increased in human heart failure.[1–3] Although this helps to maintain contractile force, blood pressure, and blood flow to vital organs, it becomes detrimental in the long run.[4,5] β$_1$- and β$_2$-adrenoceptors are the most abundant cardiac adrenoceptors with the expression of β$_1$-adrenoceptors exceeding that of β$_2$-adrenoceptors by four-fold in the normal (human) heart.[4] β$_1$-adrenoceptors exclusively couple with stimulatory G proteins (G$_s$), whereas β$_2$-adrenoceptors have been shown to directly interact with both G$_s$ and inhibitory G (G$_i$) proteins.[6,7] In human heart failure, expression of sarcolemmal β$_1$-adrenoceptors and their coupling with G$_s$ decreases.[8] On the other hand, an increase of 'promiscuous' β$_2$- relative to β$_1$-adrenoceptors and an increased expression of G$_i$ (particularly the isoform G$_{i2}$) are observed.[8,9] This latter finding can be interpreted as an attempt to

shield the heart against catecholamines since Rau *et al.*[10] have shown that a G$_{i2}$ increase similar to that found in human heart failure is sufficient to significantly reduce adenylyl cyclase-mediated cAMP production. This and other findings support the hypothesis that signalling via G$_i$ proteins is cardioprotective.[11–14] Of interest, overexpression of both β$_1$- and β$_2$-adrenoceptors has been shown to induce cardiac hypertrophy and heart failure in mice, respectively.[15,16] However, levels of overexpression necessary to cause heart failure seem to be higher for β$_2$-adrenoceptors that in contrast to β$_1$-adrenoceptors couple with both G$_s$ and G$_i$.[15,16] Nonetheless, cardioprotective effects mediated by G$_i$ proteins are still a matter of debate, particularly regarding the cardiac condition, e.g. normal vs. pathological. To address this issue, we investigated whether lack of the catalytic G$_{i2}$ subunit (Gα$_{i2}$) affects cardiac function and survival in the murine heart failure model of cardiac β$_1$-adrenoceptor overexpression compared with wild-type mice and mice either lacking Gα$_{i2}$ or overexpressing β$_1$. Parts of this work have already been published as a conference abstract.[17]

2. Methods

2.1 Mouse models used

Animals were kept in individually ventilated cages with a 12/12 h dark/light cycle and food and water *ad libitum*. Mice ubiquitary lacking Gα$_{i2}$ (Gα$_{i2}^{-/-}$) have originally been generated on a 129Sv background, but subsequently been backcrossed to C57BL/6J.[13,18,19] Mice with a cardiac-specific overexpression of the human β$_1$-adrenoceptor (β$_1$-tg) have originally been generated on a FVB/N background.[15] For the current study, we backcrossed this line on a C57BL/6J background (>10 generations) to allow for mating with Gα$_{i2}$ knockout mice to generate β$_1$-transgenic animals deficient of Gα$_{i2}^{-/-}$ (β$_1$-tg/Gα$_{i2}^{-/-}$). As control animals we used age-matched wild-type littermates. Animals of both sexes were used for our study. For genotyping, tail-clips from 3-week-old mice were used. Genomic DNA was prepared and genotyping PCR for Gα$_{i2}$ and the β$_1$-receptor was performed as described previously.[13,20] Animals were killed by cervical dislocation. Animal breeding, maintenance, and experiments were approved by the responsible federal state authority (Landesamt fuer Natur-, Umwelt- und Verbraucherschutz Nordrhein-Westfalen; reference: 87-51.04.2010.A078). All animal experiments comply with the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.

2.2 Survival analysis

All genotypes were monitored for a minimum period of 2 years. Kaplan–Meier survival curves were used to determine mean survival time of each mouse line. Spontaneous death was defined as the event of interest, while killing an animal was a censored event. Mice used for breeding were excluded from our analysis. Numbers of mice included in our survival analysis were 200, 34, 37, and 192 for C57BL/6 (wild type), Gα$_{i2}^{-/-}$, β$_1$-tg/Gα$_{i2}^{-/-}$, and β$_1$-tg mice, respectively. Numbers of spontaneous deaths that occurred during an observation period were 9 (C57BL/6), 10 (Gα$_{i2}^{-/-}$), 21 (β$_1$-tg/Gα$_{i2}^{-/-}$), and 22 (β$_1$-tg).

2.3 Echocardiography

At an age of 302 ± 19 days, mice (*n* = 5−7 of every genotype) were examined by echocardiography under light inhalation anaesthesia with oxygen and 1.5% isoflurane through a nose cap. Chests were epilated and the animals were placed on a heating table to prevent hypothermia and cardiodepressive effects. For the experiments, a commercial echocardiography system (Philips iE33 ultrasonic system, 'Qlab Cardiac Analysis' Software; Philips Healthcare, Hamburg, Germany) equipped with a 15 MHz linear array transducer (L15-io7) allowing frame rates of 270 Hz was used. The transducer was moved along the parasternal long and short axis of the left ventricle, and

loops of 3 s duration were recorded in one-dimensional (M-mode) and two-dimensional planes. To monitor the heart rate of the animals and thus anaesthesia during measurements, an ECG was derived. For reconstructive three-dimensional echocardiography, multiple short-axis slices were recorded every 500 μm using a millimetre screw-tripod.[21,22]

2.4 Ventricle-to-body weight ratio

Before killing a mouse, its body weight was measured. For determining ventricular weight, hearts were excised immediately after killing by cervical dislocation, atria were cut, and intraventricular blood removed. We analysed 11, 8, 7, and 14 hearts of C57BL/6 (wild-type), Gα$_{i2}^{-/-}$, β$_1$-tg/Gα$_{i2}^{-/-}$, and β$_1$-tg mice, respectively, including those from mice examined by echocardiography.

2.5 Quantitative real-time PCR

For quantitative real-time PCR (qPCR), we used ventricles that were stored at −80°C immediately after excision. qPCR analysis was performed to determine relative ventricular mRNA expression levels of the cardiomyopathy markers atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), the G$_i$ proteins Gα$_{i2}$ and Gα$_{i3}$, and the cardiac protein kinase A (PKA) targets ryanodine receptor 2 (RYR2), troponin I (TnI, TNNI3), and phospholamban (PLB). All steps of analysis were performed following the manufacturer's protocol by QIAGEN (Hilden, Germany). mRNA isolation was performed with the RNeasy® Fibrous Tissue Kit (QIAGEN). Quality and quantity of the purified mRNA were controlled using a NanoDrop 8000 Spectrophotometer (Thermo Scientific, Waltham, MA, USA). For reverse transcription, the QuantiTect® Reverse Transcription Kit was used (QIAGEN). qPCR was run in triple repeats with the QuantiTect SYBR® Green PCR Kit (QIAGEN). Specific primer pairs for Gα$_{i2}$, BNP, RYR2, TNNI3, and PLB were designed using Roche Assay Design Center: Gα$_{i2}$: 5′-AAG ACC TGT CCG GTG TCA T-3′ for sense and 5′-GGG ATG TAG TCA CTC TGT GC-3′ for antisense. BNP: 5′-GTC AGT CGT TTG GGC TGT AAC-3′ for sense and 5′-AGA CCC AGG CAG AGT CAG AA-3′ for antisense. RYR2: 5′-TTC ACA CCT GTT CCT GTG GA-3′ for sense and 5′-TTT CTC TTA TCC TTT CCA GGT GA-3′ for antisense. TNNI3: 5′-GAG CCA CAC GCC AAG AAA-3′ for sense and 5′-GCC CCT TCT CTC CAC GTC-3′ for antisense. PLB: 5′-CTG TGA CGA TCA CCG AAG C-3′ for sense and 5′-TGG TCA AGA GAA AGA TAA AAA GTT GA-3′ for antisense. Primer pairs for Gα$_{i3}$ and ANP were reported previously.[23–25] S29 served as a housekeeping gene. The qPCR was started with an initial step of incubation at 95°C for 15 min. Next, 45 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 25 s, and elongation at 72°C for 10 s were run with a transition rate of 20°C per second. Finally, a melting curve analysis was applied to check for product purity at 64°C for 1 min with a transition rate of 0.1°C per second.

2.6 Western blot analysis

Ventricles from three different animals per genotype were isolated, separately homogenized, and individually analysed. Tissue was homogenized in protein lysis buffer containing 21 mM Tris−HCl, pH 8.3, 0.67% SDS, 238 mM β-mercapoethanol, and 0.2 mM PMSF. Gα protein isoform separation was performed in gels containing 6 M urea. In total, 20 μg per lysate was loaded. To verify Gα$_{i3}$ antibody specificity, ventricle lysates isolated from Gα$_{i3}$-deficient mice were loaded.[26] The proteins were visualized by immunodetection using the following primary antibodies described elsewhere:[27–30] rabbit anti-Gα$_{i2}$ (1 : 8000) and rabbit anti-Gα$_{i3}$ (1 : 5000). Equal loading was verified with antibodies against rabbit anti-β-actin (1 : 10 000). The protein levels of Gα$_{i2}$ and Gα$_{i3}$ were quantified using the densitometric analysis software (Image Lab; Bio-Rad, Gräfelfing, Germany) and were normalized to the β-actin levels of the same samples. For each ventricle, immune blots were run in triplicates or quadruplicates. Homogenates of the four different genotypes were always loaded on the same gel and analysed in parallel.

2.7 Radioligand-binding experiments

Hearts from 4- to 6-month-old mice of both sexes were isolated in ice-cold phosphate buffer saline, frozen in liquid nitrogen, and stored at $-80°C$ until membrane preparation. Ventricular tissue was homogenized in a 0.32 M sucrose solution and centrifuged for 11 min at $300 \times g$. Supernatants were centrifuged for 41 min at $80\,000 \times g$ and pellets resuspended in aqua destillata. All preparation steps were carried out at $4°C$. Finally, aliquots of 0.5 mL were frozen in liquid nitrogen and stored at $-80°C$. Protein content was determined according to Lowry and ranged from 5.4 to 7.7 mg/mL. For saturation-binding experiments, membranes were incubated in Tris−HCl buffer (Tris 50 mM, pH 7.4; EDTA 5 mM) of a final volume of 1.5 mL at $23°C$ containing $50-300\,\mu g$ protein. Eight concentrations (0.025−1.5 nM) of $[^3H]$CGP 12177 (specific activity: 37.7 Ci/mmol; PerkinElmer, Rodgau, Germany) were used to quantify β-adrenoceptor expression. Non-specific binding was measured in the presence of 10 μM propranolol or atropine (Sigma-Aldrich, Steinheim, Germany). Incubation was stopped after 90 min by rapid filtration through polyethylenimine (0.1%)-pretreated glass microfiber sheets using a Brandel cell harvester. Filter-bound radio-activity was detected by liquid scintillation counting. Fraction of $β_2$--adrenoceptor binding of $[^3H]$CGP 12177 was estimated in the presence of 70 nM ICI 118,551 (Sigma-Aldrich). Quality of the used homogenates was similar, as confirmed by muscarinic receptor levels determined with six concentrations (0.5−1.5 nM) of $[^3H]N$-methylscopolamine (specific activity: 84.1 Ci/mmol; PerkinElmer). Binding curves were analysed by non-linear curve fitting using the software GraphPad Prism®. Data points were fitted by a one-site-specific binding model.

2.8 Statistical analysis

Data are given as mean $\pm$ S.E.M. Survival times were calculated by Kaplan−Meier estimation. Differences were determined by the log-rank test. Cardiac functional parameters obtained from echocardiography and ventricle-to-body weight ratios were compared by ANOVA followed by *post hoc* tests (Bonferroni). mRNA expression ratios using C_t values obtained by qPCR were compared using the REST-2009® software.[31] Distribution between sexes was compared by Fisher's exact test. *P*-values <0.05 were defined to indicate statistically significant differences.

3. Results

3.1 Gross phenotype

Genotypes were distributed as expectable according to the Mendelian law (not shown). Overall distribution between sexes was nearly equal (51% male and 49% female) and did not differ between genotypes (not shown). All mice behaved normally and no overt phenotype was observed. Deaths occurred suddenly and were only in single cases preceded by unspecific symptoms like reduced movement or seclusive behaviour. Gastrointestinal symptoms as described previously for mice lacking $Gα_{i2}$ were not seen in our study, presumably due to keeping the mice in individually ventilated cages.[32]

3.2 Survival analysis

Kaplan−Meyer estimation revealed a significantly enhanced mortality of β₁-transgenic mice deficient of $Gα_{i2}^{-/-}$ (β₁-tg/$Gα_{i2}^{-/-}$) compared with all other genotypes (*Figure 1*). Mean survival time was reduced to 363 ± 21 days (22 deaths out of 37 mice in total) compared with 669 ± 31 for wild-type mice (9/200), 489 ± 37 for $Gα_{i2}^{-/-}$ (10/34), and 561 ± 20 for β₁-tg mice (21/192). Though survival time of mice only lacking $Gα_{i2}$ was significantly reduced, too, this effect was significantly more dramatic in β₁-tg/$Gα_{i2}^{-/-}$ mice ($P = 0.02$ in a log-rank test compared with $Gα_{i2}^{-/-}$). Of note, survival curves of β₁-tg/$Gα_{i2}^{-/-}$ and

mice only lacking $Gα_{i2}$ were indistinguishable up to an age of $\sim$300 days. Similar to recent findings by another group, survival curves of wild-type and β₁-tg mice started to differ around an age of 13 months,[33] though in our study the difference in mean survival times derived from Kaplan−Meier analysis did not reach statistical significance. Fifty per cent of deaths in the β₁-tg/$Gα_{i2}^{-/-}$ group already occurred up to an age of 300 days. Since survival curves thus indicated a rather early onset of detrimental effects, we defined 300 days as the target age for further experiments. Moreover, this allowed for a sufficient number of animals available for *in vivo* examination. Of note, the choice of an age of 300 days excluded a considerable number of β₁-tg/$Gα_{i2}^{-/-}$ (and to a lesser extent $Gα_{i2}^{-/-}$) animals from further analysis due to early death. This might have biased the obtained data, e.g. if animals were still living at Day 300 because they have been less affected than those that had already died.

3.3 Echocardiographic analysis of cardiac morphology and function

At a mean age of 300 days (range: 273−326), the ventricle-to-body weight ratio of β₁-tg/$Gα_{i2}^{-/-}$ mice was significantly increased ($0.71 \pm 0.06\%$, $n = 5$) compared with wild-type mice ($0.48 \pm 0.02\%$, $n = 11$), $Gα_{i2}^{-/-}$ ($0.50 \pm 0.01\%$, $n = 8$), and β₁-tg mice ($0.44 \pm 0.01\%$, $n = 14$), thus indicating cardiac hypertrophy in β₁-transgenic mice lacking $Gα_{i2}$ (*Figure 2*). This was confirmed in echocardiographic examinations of anaesthetized mice of the same age. Ventricles of β₁-tg/$Gα_{i2}^{-/-}$ mice appeared to be clearly enlarged (see Supplementary material online, *Figure S1*). End-systolic and end-diastolic ventricular volumes were similar when comparing wild-type, $Gα_{i2}^{-/-}$, and β₁-tg mice, but significantly


Figure 1 Kaplan−Meier survival curves of wild-type, knockout, and transgenic mice. Vertical bars indicate a censoring event (usually representing killing of an animal for experimental purposes). Mean survival times were significantly decreased for $Gα_{i2}^{-/-}$ and β₁-tg/$Gα_{i2}^{-/-}$ mice, each compared with all other genotypes. However, compared with $Gα_{i2}^{-/-}$ mice, survival time was significantly lower in β₁-tg/$Gα_{i2}^{-/-}$ mice (log-rank test). The number of animals underlying survival analysis was 200, 34, 37, and 192 for wild-type (C57BL/6), $Gα_{i2}^{-/-}$, β₁-tg/$Gα_{i2}^{-/-}$, and β₁-tg mice, respectively. Vertical dashed lines label age range of mice used for further investigations (*Figures 2, 3, 5−7*).

enhanced in β$_1$-tg/Gα$_{i2}^{-/-}$ mice compared with all other genotypes (*Figure 3A* and *B*). Furthermore, ejection fraction was significantly reduced in β$_1$-tg/Gα$_{i2}^{-/-}$ mice (*Figure 3C*). Significantly increased ventricular length and reduced myocardial thickness in β$_1$-tg/Gα$_{i2}^{-/-}$ mice indicated a dilative cardiomyopathy (data not shown; compare Supplementary material online, *Figure S1*).


Figure 2 Ventricle-to-body weight ratios of knockout and transgenic mice indicate a significant cardiac hypertrophy of β$_1$-tg/Gα$_{i2}^{-/-}$ mice. The number of animals used for analysis was 11, 8, 5, and 14 for wild-type (C57BL/6), Gα$_{i2}^{-/-}$, β$_1$-tg/Gα$_{i2}^{-/-}$, and β$_1$-tg mice, respectively. Age range of examined mice was 301 ± 3 days. Asterisks indicate a significant difference compared with all other genotypes in Bonferroni post-tests following ANOVA (*P* < 0.01).

3.4 Expression of β-adrenoceptors and comparison to β-transgenic mice on an FVB/N background

Using saturation radioligand-binding experiments (*Figure 4*), we confirmed significant overexpression of β-adrenoceptors in 4- to 6-month-old β$_1$-tg mice (B$_{max}$ 609 ± 18 vs. 8.4 ± 1.6 fmol/mg in C57BL/6 wild-type mice). In wild-type ventricles, ∼80% of radioligand binding was due to β$_1$-adrenoceptors, while in transgenic mice virtually all detected receptors were β$_1$-adrenoceptors (data not shown). Of note, on the original FVB/N background, we found the overexpression level to be more than two-fold higher (B$_{max}$: 1425 ± 68 fmol/mg) than on a C57BL/6 background. Furthermore, in FVB/N-based β$_1$-transgenic mice, mean survival time was significantly reduced (402 ± 15 days). Similar to (C57BL/6-based) β$_1$-tg/Gα$_{i2}^{-/-}$ mice, ventricle-to-body weight ratio was increased (0.62 ± 0.03 vs. 0.52 ± 0.02% in FVB/N wild-type mice; *P* < 0.05; *n* = 10 and 7, respectively) and cardiac function impaired (e.g. ejection fraction: 21 ± 1 vs. 41 ± 2% in FVB/N wild-type mice; *P* < 0.01; *n* = 5 and 6, respectively) at a mean age of 307 ± 6 days (range 276–330).

3.5 Expression of G$_i$ proteins

Expression of Gα$_{i2}$ mRNA was not detectable in Gα$_{i2}$ knockout mice (*Figure 5A*). We found that the lack of Gα$_{i2}$ was accompanied by an increased expression of Gα$_{i3}$ mRNA, both on a wild-type and on a β$_1$-transgenic background (*Figure 5B*). Expression of neither Gα$_{i2}$ nor Gα$_{i3}$ mRNA was significantly altered in hearts of mice being only transgenic for the β$_1$-adrenoceptor. Immunoblot analysis of ventricle


Figure 3 Morphological and functional parameters obtained by echocardiography. End-systolic (*A*) and -diastolic (*B*) left ventricular volumes and the ejection fraction (*C*) were significantly impaired in β$_1$-tg/Gα$_{i2}^{-/-}$ mice compared with all other genotypes indicating overt heart failure. Heart rate (*D*) was similar for all investigated genotypes. The number of animals used for analysis was 5, 6, 6, and 7 for wild-type (C57BL/6), Gα$_{i2}^{-/-}$, β$_1$-tg/Gα$_{i2}^{-/-}$, and β$_1$-tg mice, respectively. Age range of examined mice was 307 ± 3 days. Asterisks indicate significant differences compared with all other genotypes in Bonferroni post-tests following ANOVA (*P* < 0.05, **P* < 0.01).

Figure 4 Ventricular β-adrenoceptor expression obtained by radioligand binding in (*A*) wild-type and (*B*) β₁ overexpressing mice (β₁-tg) at an age of 4–6 months. In both C57BL/6- and FVB/N-based β₁-tg mice, β-adrenoceptor expression was strikingly increased compared with the corresponding wild-type. Of note, the (over-) expression level was higher in tissue from transgenic mice with an FVB/N background. Each homogenate (10–12 ventricles per genotype) was used in three independent experiments in duplicates.

homogenates revealed $G\alpha_{i2}$ protein expression in ventricles of C57BL/6 and β₁-tg mice, whereas the $G\alpha_{i2}$ protein was absent in $G\alpha_{i2}^{-/-}$ and β₁-tg/$G\alpha_{i2}^{-/-}$ ventricles (*Figure 5C* and *E*). $G\alpha_{i3}$ protein levels were significantly up-regulated in $G\alpha_{i2}^{-/-}$ ($340 \pm 90\%$) and β₁-tg/$G\alpha_{i2}^{-/-}$ ($394 \pm 80\%$) ventricles compared with C57BL/6 and β₁-tg animals and absent in $G\alpha_{i3}$-deficient ventricles (*Figure 5D* and *F*).

3.6 Expression of hypertrophy markers and PKA targets

According to our morphological and functional findings, qPCR analysis revealed a significant up-regulation of the cardiomyopathy markers ANP (*Figure 6A*) and BNP (*Figure 6B*) in ventricular tissue of β₁-tg/$G\alpha_{i2}^{-/-}$ compared with wild-type mice. However, mRNA expression levels of ANP were also significantly increased in $G\alpha_{i2}^{-/-}$ mice and showed a tendency to be higher in β₁-tg animals (*Figure 6A*). BNP levels were unchanged in $G\alpha_{i2}^{-/-}$, but significantly increased in β₁-tg mice (*Figure 6B*). We tested for mRNA expression of the calcium release channel (ryanodine receptor) RYR2, the cardiac TnI TNNI3, and PLB as known targets of PKA-mediated phosphorylation (*Figure 7*). Compared with C57BL/6 wild-type mice, no differences were seen for RYR2 mRNA, but there was a significantly reduced expression of TnI in ventricles of β₁-tg/$G\alpha_{i2}^{-/-}$ ($63 \pm 7\%$ of wild type), and of PLB in

ventricles of both β₁-tg and β₁-tg/$G\alpha_{i2}^{-/-}$ (43 ± 6 and $47 \pm 12\%$ of wild type, respectively).

4. Discussion

In line with the idea of cardioprotective signalling mediated by G_i proteins, we show here that the lack of $G\alpha_{i2}$ in mice overexpressing cardiac β₁-adrenoceptors was detrimental: cardiac contractility was significantly depressed and survival time dramatically reduced. Mice deficient for either $G\alpha_{i2}$ or $G\alpha_{i3}$ have been reported to have no overt cardiac phenotype *in vivo* (echocardiography) and *ex vivo* (isolated whole hearts and myocytes).[34] This is in perfect agreement with our current data obtained from $G\alpha_{i2}$-deficient mice in the same range of age. Survival time of $G\alpha_{i2}$-deficient mice was reduced, but reduction was significantly more pronounced in β₁-tg/$G\alpha_{i2}^{-/-}$ mice. Of interest, survival curves of β₁-tg/$G\alpha_{i2}^{-/-}$ and mice only lacking $G\alpha_{i2}$ were indistinguishable up to an age of ~300 days. Since survival curves of β₁-tg mice start to drop rather late (this study and Lee *et al.*[33]), it is tempting to speculate that the early effect on mortality (up to Day 300) is due to $G\alpha_{i2}$ deficiency while the detrimental effect observed beyond 300 days of age is related to the cardiac overexpression of β₁-adrenoceptors. Given that cardiac function of mice only lacking $G\alpha_{i2}$ was unaffected at an age of 300 days, a cause of death other than reduced pump function has to be supposed. In a previous study, mice with both a $G\alpha_{i2}$ knockout and a cardiac-specific overexpression of β₂-adrenoceptors have been shown to be not viable.[13] This fatal outcome might be explained by direct coupling of β₂-adrenoceptors to G_i proteins. The drastic effect of $G\alpha_{i2}$ deficiency on top of cardiac β₁-adrenoceptor overexpression seen in our current study is rather surprising given that β₁-adrenoceptors are thought to exclusively couple with G_s proteins. However, recent work suggests a role for G_i in modulation of β₁-mediated effects. Melsom *et al.*[35] showed that inhibition of G_i proteins by pertussis toxin (PTX) not only enhanced cAMP accumulation following selective stimulation of either β₁- or β₂-adrenoceptors, but also increased inotropic potency of β₁- and β₂-adrenergic agonists, respectively. Another work by the same group indicates that G_i exerts intrinsic receptor-independent inhibitory activity on adenylyl cyclase.[36]

4.1 β₁-Adrenoceptor overexpression

Like in mice overexpressing the cardiac β₂-adrenoceptor, the phenotype of β₁-transgenic mice seems to depend on the extent of overexpression. A higher expression level of β₁-adrenoceptors led to an earlier and more pronounced hypertrophy of cardiomyocytes and a higher sensitivity of contractile response to dobutamine.[15] We found that after back-crossing on a C57BL/6 background, cardiac β-adrenoceptor overexpression was lower compared with FVB/N-based β₁-transgenic mice. This might explain why survival curves of β₁-transgenic mice on a C57BL/6 background start to drop later (in accordance to findings of another group that independently back-crossed the β₁-transgeni mice mouse of Engelhardt *et al.* on a C57BL/6 background).[15,33] In good agreement, cardiac function was already impaired at an age of 300 days in FVB/N-, but not in C57BL/6-based β₁-transgenic mice.

4.2 cAMP-dependent adrenergic signalling

That there was overt cardiomyopathy in (C57BL/6-based) β₁-transgenic mice additionally lacking $G\alpha_{i2}$ thus might be explained by a dual mechanism: increased β₁-adrenergic drive and lack of protection by $G\alpha_{i2}$. Engelhardt *et al.*[37] found an increased expression of the cardiac

Figure 5 Ventricular expression of cardiac G$_i$. (*A*) Gα$_{i2}$ mRNA was not detectable in knockout mice on either wild-type or β$_1$-transgenic background and expressed at wild-type level in mice only transgenic for the β$_1$-adrenoceptor. (*B*) Gα$_{i3}$ mRNA expression was significantly increased compared with wild-type mice in animals lacking Gα$_{i2}$ on both a wild-type and β$_1$-transgenic background, respectively. The number of animals used for qPCR analysis was 3–4 for each genotype. Age range of examined mice was 302 ± 4 days. Asterisks indicate significant differences compared with mRNA expression levels of age-matched wild-type mice in an REST$^®$ analysis (*$P < 0.05$, **$P < 0.01$). (*C*) Representative immunoblots for the Gα$_{i2}$ protein in ventricle homogenates. The Gα$_{i2}$ protein was absent in Gα$_{i2}^{-/-}$ and β$_1$-tg/Gα$_{i2}^{-/-}$ mice. (*E*) Statistical analysis of Gα$_{i2}$ expression levels. (*D*) Representative immunoblot for the Gα$_{i3}$ protein in ventricle homogenates. To verify Gα$_{i3}$ antibody specificity, Gα$_{i3}$-deficient ventricle homogenates were loaded in addition. (*F*) Statistical analysis of Gα$_{i3}$ expression levels. A significant up-regulation of Gα$_{i3}$ protein levels was detectable in Gα$_{i2}^{-/-}$ and β$_1$-tg/Gα$_{i2}^{-/-}$ mice. For western blots, individual homogenates from three animals per genotype were analysed in 3–4 independent experiments. β-Actin was used to demonstrate equal loading of the gels. Asterisks indicate significant differences in Bonferroni post-tests following ANOVA (*$P < 0.05$; **$P < 0.01$).

Na$^+$-/H$^+$-exchanger NHE1 in β$_1$-adrenoceptor transgenic mice and showed that NHE1 inhibition prevented heart failure in this mouse model. Since NHE1 activity is modulated by cAMP, one might speculate that, in the β$_1$-overexpression model, lack of Gα$_{i2}$ further aggravates NHE1-dependent effects leading to accelerated development of cardiac dysfunction and eventually mortality in our study.[38] Though only an indirect hint, we looked at the expression of other potential phosphorylation targets at the mRNA level. Altered phosphorylation of the calcium release channel RYR2 has been attributed to heart failure and cardiac arrhythmia, though there is an ongoing controversial discussion.[39] In our mouse models, RYR2 mRNA expression was unchanged, but we cannot exclude that enhanced phosphorylation due to a maintained increase of β-adrenergic tone might be involved in the early mortality we observed in β$_1$-transgenic mice lacking Gα$_{i2}$. TnI seems to mediate both lusitropic and inotropic responses following β-adrenergic stimulation in murine hearts,[40] though the role of TnI and its phosphorylation in healthy and failing hearts is matter of

debate.[41] We found a significant reduction of TnI expression at the mRNA level in β$_1$-transgenic mice lacking Gα$_{i2}$. This might be related to their detrimental outcome since it has been shown that TnI knockout leads to heart failure in adult mice.[42] Both β$_1$-transgenic mouse lines investigated in our study (β$_1$-tg and β$_1$-tg/Gα$_{i2}^{-/-}$) showed a significant reduction of PLB mRNA expression. Engelhardt *et al.*[43] found no alteration of PLB expression in β$_1$-transgenic mice at an age of 2 months, but an increased PLB phosphorylation indicating enhanced β-adrenergic signalling. The decrease of PLB expression observed at an age of ∼9–10 months in our study might be compensatory by restoring the function of the SR calcium pump SERCA2A.[44] Indeed, knockout of PLB in β-transgenic mouse hearts has been shown to rescue its heart failure phenotype.[45] However, there seems to be a critical difference between mice and men because human PLB null has been shown to result in lethal cardiomyopathy.[46] Of note, PKA-dependent phosphorylation of β$_2$-adrenoceptors has been shown to drive a switch from G$_s$ to G$_i$ signalling,[47] though this mechanism is matter of

Figure 6 Expression of cardiac hypertrophy markers in murine ventricles. Increased mRNA expression of ANP (*A*) and BNP (*B*) compared with wild-type levels confirmed morphological parameters indicating cardiac hypertrophy in β_1-tg/$G\alpha_{i2}^{-/-}$ mice. The number of animals used for analysis was 3−4 for each genotype. Age range of examined mice was 302 ± 4 days. Asterisks indicate significant differences compared with mRNA expression levels of age-matched wild-type mice in an REST® analysis (*$P < 0.05$, **$P < 0.01$).

debate. β_1-Adrenoceptor overexpression thus might enhance β_2-adrenoceptor-mediated G_i signalling. This would explain the pronounced effect of $G\alpha_{i2}$ deficiency in β_1-transgenic mice compared with mice with an otherwise wild-type background seen in our study.

4.3 G_i-mediated adrenergic signalling

Irrespective of the (disputed) role of β_2-adrenoceptor regulation by β_1-adrenoceptors, the accepted role of G_i proteins for β_2-adrenoceptor signalling should be considered. Communal *et al.*[48] have described opposing β-adrenoceptor-mediated effects on apoptosis in rat cardiomyocytes in terms of enhancement via β_1- but attenuation via β_2-adrenoceptors. Indeed, the combination of β_1-adrenoceptor blockers and β_2-adrenoceptor agonists has been shown to be superior to only β_1-adrenoceptor antagonists in treating cardiomyopathy in rodents.[49,50] Though the above-mentioned anti-apoptotic effect by β_2-adrenergic signalling was attributed to G_i-dependent activation of p38, the finding that overexpression of a dominant negative p38 isoform rescued cardiomyopathy of β_2- but not β_1-adrenoceptor transgenic mice argues against a role of this mechanism in our study.[51,52] Kohler *et al.*[14] have recently shown that following an ischaemia/reperfusion (I/R) protocol, cardiac infarct size was significantly increased in mice deficient for $G\alpha_{i2}$. Also in a murine I/R model, similar findings have been obtained with an induced cardiac expression of a G_i inhibitor peptide.[11] Taken together with our current study on β_1-adrenoceptor


Figure 7 Ventricular mRNA expression of the PKA targets RYR2, TnI, and PLB. (*A*) RYR2 expression was similar in all genotypes. (*B*) TnI expression was significantly reduced in β_1-tg/$G\alpha_{i2}^{-/-}$ ventricles compared with wild-type (C57BL/6) tissue. (*C*) In both β_1-adrenoceptor overexpressing mouse lines (β_1-tg and β_1-tg/$G\alpha_{i2}^{-/-}$), ventricular PLB expression was significantly reduced compared with wild-type (C57BL/6) tissue. The number of animals used for analysis was 3−4 for each genotype. Age range of examined mice was 288 ± 9 days. Asterisks indicate significant differences compared with mRNA expression levels of age-matched wild-type mice in an REST® analysis (*$P < 0.05$).

overexpressing mice, these data suggest that the cardioprotective role of G_i proteins might become evident under certain circumstances only, i.e. cardiac stress and/or disease. Not all studies support the idea of G_i proteins being protective in cardiomyopathy and heart failure. The beneficial effect of combined treatment with a β_1-adrenoceptor blocker and a β_2-adrenoceptor agonist following myocardial infarction in rats was also seen when using fenoterol that has been shown to mediate β_2-adrenergic effects independent of G_i proteins.[50,53] Of note, the

reported G protein selectivity of stereoisomers of fenoterol has recently been challenged.[54] In a mouse model of dilative cardiomyopathy due to cre-recombinase overexpression, an increase of G$_i$ signalling by knock-in of a mutated Gα$_{i2}$ did not improve but even worsen ventricular hypertrophy and mortality.[55] In a pathophysiologically more relevant model, Hussain et al.[56] found no change in G$_i$ activity in rat heart failure following myocardial infarction: despite a significant increase of Gα$_{i2}$ protein by 50% G$_i$ inhibition by PTX treatment, here did neither change baseline contractility nor inotropic response following β-adrenergic stimulation in ventricular strips from failing hearts.

4.4 Role of G$_{i2}$ vs. G$_{i3}$

The putative differential roles of the most abundant cardiac G$_i$ isoforms Gα$_{i2}$ and Gα$_{i3}$ are still a matter of debate. As mentioned above, mice with cardiac-specific overexpression of β$_2$-adrenoceptors were not viable, if they in addition were deficient of Gα$_{i2}$.[13] In the same study, heterozygous knockout of Gα$_{i2}$ in β$_2$-transgenic mice caused a reduced activity of ventricular L-type Ca^{2+} channels that was attributed to an increased expression of Gα$_{i3}$. These data led us to the hypothesis that Gα$_{i2}$ is cardioprotective, whereas Gα$_{i3}$ is rather of regulatory relevance. In a subsequent study, this hypothesis was supported by our finding that, in Gα$_{i2}$ knockout mice, cardiac Gα$_{i3}$ expression was up-regulated and accordingly ventricular Ca^{2+}-current density was decreased while, in mice lacking Gα$_{i3}$, Ca^{2+}-current density was enhanced despite an increased Gα$_{i2}$ expression.[24] Kohler et al.[14] confirmed an increased cardiac Gα$_{i2}$ expression in mice lacking Gα$_{i3}$ and found ventricular infarct size following ischaemia to be reduced here compared with wild-type mice or mice lacking Gα$_{i2}$.

5. Conclusion

In conclusion, our data support the idea of the G$_i$ protein Gα$_{i2}$ to be cardioprotective. Of interest, this was observed in β$_1$-adrenoceptor overexpressing mice, i.e. a mouse model of cardiac stress not directly involving G$_i$ signalling. The lack of Gα$_{i2}$ seemed to aggravate rather than cause cardiac dysfunction. The observed up-regulation of Gα$_{i3}$ was not sufficient to compensate for Gα$_{i2}$ deficiency, suggesting an isoform-specific or a concentration-dependent mechanism to be elucidated in further studies.

Supplementary material

Supplementary material is available at *Cardiovascular Research* online.

References

1. Cohn JN. The sympathetic nervous system in heart failure. *J Cardiovasc Pharmacol* 1989;**14**(Suppl 5):S57–S61.
2. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation* 1990;**82**:1724–1729.
3. Francis GS, Goldsmith SR, Ziesche SM, Cohn JN. Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. *Am J Cardiol* 1982;**49**:1152–1156.
4. Florea VG, Cohn JN. The autonomic nervous system and heart failure. *Circ Res* 2014;**114**:1815–1826.
5. El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. *Heart Fail Rev* 2009;**14**:225–241.
6. Ahles A, Engelhardt S. Polymorphic variants of adrenoceptors: pharmacology, physiology, and role in disease. *Pharmacol Rev* 2014;**66**:598–637.
7. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, Han Q. Subtype-specific alpha1- and beta-adrenoceptor signaling in the heart. *Trends Pharmacol Sci* 2006;**27**:330–337.
8. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. *Circ Res* 1986;**59**:297–309.
9. Eschenhagen T. G proteins and the heart. *Cell Biol Int* 1993;**17**:723–749.
10. Rau T, Nose M, Remmers U, Weil J, Weissmuller A, Davia K, Harding S, Peppel K, Koch WJ, Eschenhagen T. Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes. *FASEB J* 2003;**17**:523–525.
11. DeGeorge BR Jr, Gao E, Boucher M, Vinge LE, Martini JS, Raake PW, Chuprun JK, Harris DM, Kim GW, Soltys S, Eckhart AD, Koch WJ. Targeted inhibition of cardiomyocyte G$_i$ signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. *Circulation* 2008;**117**:1378–1387.
12. El-Armouche A, Zolk O, Rau T, Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. *Cardiovasc Res* 2003;**60**:478–487.
13. Foerster K, Groner F, Matthes J, Koch WJ, Birnbaumer L, Herzig S. Cardioprotection specific for the G protein G$_{i2}$ in chronic adrenergic signaling through beta 2-adrenoceptors. *Proc Natl Acad Sci USA* 2003;**100**:14475–14480.
14. Kohler D, Devanathan V, Bernardo de Oliveira Franz C, Eldh T, Novakovic A, Roth JM, Granja T, Birnbaumer L, Rosenberger P, Beer-Hammer S, Nurnberg B. Galpha$_{i2}$- and Galpha$_{i3}$-deficient mice display opposite severity of myocardial ischemia reperfusion injury. *PLoS ONE* 2014;**9**:e98325.
15. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. *Proc Natl Acad Sci USA* 1999;**96**:7059–7064.
16. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW II. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. *Circulation* 2000;**101**:1707–1714.
17. Keller K, Maaß M, Dizayee S, Müller-Ehmsen J, Birnbaumer L, Engelhardt S, Herzig S, Matthes J. Reduction of survival and development of cardiac hypertrophy by G$_{i2}$ deficiency in beta1-adrenoceptor overexpressing mice. *Naunyn Schmiedebergs Arch Pharmacol* 2014;**387**:S56.
18. Rudolph U, Brabet P, Hasty P, Bradley A, Birnbaumer L. Disruption of the G(i2) alpha locus in embryonic stem cells and mice: a modified hit and run strategy with detection by a PCR dependent on gap repair. *Transgenic Res* 1993;**2**:345–355.
19. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. *Nat Genet* 1995;**10**:143–150.
20. Foerster K, Kaeferstein T, Groner F, Engelhardt S, Matthes J, Koch WJ, Lohse MJ, Herzig S. Calcium channel function and regulation in beta 1- and beta 2-adrenoceptor transgenic mice. *Naunyn Schmiedebergs Arch Pharmacol* 2004;**369**:490–495.
21. Ghanem A, Troatz C, Elhafi N, Dewald O, Heeschen C, Nickenig G, Stypmann J, Tiemann K. Quantitation of myocardial borderzone using reconstructive 3-D echocardiography after chronic infarction in rats: incremental value of low-dose dobutamine. *Ultrasound Med Biol* 2008;**34**:559–566.
22. Kanno S, Lerner DL, Schuessler RB, Betsuyaku T, Yamada KA, Saffitz JE, Kovacs A. Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction. *J Am Soc Echocardiogr* 2002;**15**:601–609.
23. Bai Y, Morgan EE, Giovannucci DR, Pierre SV, Philipson KD, Askari A, Liu L. Different roles of the cardiac Na$^+$/Ca^{2+}-exchanger in ouabain-induced inotropy, cell signaling, and hypertrophy. *Am J Physiol Heart Circ Physiol* 2013;**304**:H427–H435.
24. Dizayee S, Kaestner S, Kuck F, Hein P, Klein C, Piekorz RP, Meszaros J, Matthes J, Bjrnbaumer L, Nurnberg B, Herzig S. Galpha$_{i2}$- and Galpha$_{i3}$-specific regulation of voltage-dependent L-type calcium channels in cardiomyocytes. *PLoS ONE* 2011;**6**:e24979.
25. Wiege K, Le DD, Syed SN, Ali SR, Novakovic A, Beer-Hammer S, Piekorz RP, Schmidt RE, Nurnberg B, Gessner JE. Defective macrophage migration in Galpha$_{i2}$- but not Galpha$_{i3}$-deficient mice. *J Immunol* 2012;**189**:980–987.
26. Jiang M, Spicher K, Boulay G, Martin-Requero A, Dye CA, Rudolph U, Birnbaumer L. Mouse gene knockout and knockin strategies in application to alpha subunits of G$_i$/G$_o$ family of G proteins. *Methods Enzymol* 2002;**344**:277–298.

27. Exner T, Jensen ON, Mann M, Kleuss C, Nurnberg B. Posttranslational modification of Galphao1 generates Galphao3, an abundant G protein in brain. *Proc Natl Acad Sci USA* 1999;**96**:1327–1332.

28. Gohla A, Klement K, Piekorz RP, Pexa K, vom Dahl S, Spicher K, Dreval V, Haussinger D, Birnbaumer L, Nurnberg B. An obligatory requirement for the heterotrimeric G protein G_{i3} in the antiautophagic action of insulin in the liver. *Proc Natl Acad Sci USA* 2007;**104**:3003–3008.

29. Leiss V, Flockerzie K, Novakovic A, Rath M, Schonsiegel A, Birnbaumer L, Schurmann A, Harteneck C, Nurnberg B. Insulin secretion stimulated by l-arginine and its metabolite l-ornithine depends on $Galpha_{i2}$. *Am J Physiol Endocrinol Metab* 2014;**307**:E800–E812.

30. Leopoldt D, Hartenceck C, Nurnberg B. G proteins endogenously expressed in Sf 9 cells: interactions with mammalian histamine receptors. *Naunyn Schmiedebergs Arch Pharmacol* 1997;**356**:216–224.

31. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res* 2002;**30**:e36.

32. Wiege K, Ali SR, Gewecke B, Novakovic A, Konrad FM, Pexa K, Beer-Hammer S, Reutershan J, Piekorz RP, Schmidt RE, Nurnberg B, Gessner JE. $Galpha_{i2}$ is the essential $Galpha_i$ protein in immune complex-induced lung disease. *J Immunol* 2013;**190**: 324–333.

33. Lee GJ, Yan L, Vatner DE, Vatner SF. Mst1 inhibition rescues beta1-adrenergic cardiomyopathy by reducing myocyte necrosis and non-myocyte apoptosis rather than myocyte apoptosis. *Basic Res Cardiol* 2015;**110**:461.

34. Jain M, Lim CC, Nagata K, Davis VM, Milstone DS, Liao R, Mortensen RM. Targeted inactivation of Galpha(i) does not alter cardiac function or beta-adrenergic sensitivity. *Am J Physiol Heart Circ Physiol* 2001;**280**:H569–H575.

35. Melsom CB, Hussain RI, Orstavik O, Aronsen JM, Sjaastad I, Skomedal T, Osnes JB, Levy FO, Krobert KA. Non-classical regulation of beta1- and beta 2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein G_i. *Naunyn Schmiedebergs Arch Pharmacol* 2014;**387**:1177–1186.

36. Melsom CB, Orstavik O, Osnes JB, Skomedal T, Levy FO, Krobert KA. G_i proteins regulate adenylyl cyclase activity independent of receptor activation. *PLoS ONE* 2014;**9**: e106608.

37. Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ. Inhibition of $Na(+)$-$H(+)$ exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. *Circ Res* 2002;**90**:814–819.

38. Leineweber K, Heusch G, Schulz R. Regulation and role of the presynaptic and myocardial Na^+/H^+ exchanger NHE1: effects on the sympathetic nervous system in heart failure. *Cardiovasc Drug Rev* 2007;**25**:123–131.

39. Dobrev D, Wehrens XH. Role of RyR2 phosphorylation in heart failure and arrhythmias: controversies around ryanodine receptor phosphorylation in cardiac disease. *Circ Res* 2014;**114**:1311–1319; discussion 1319.

40. Layland J, Grieve DJ, Cave AC, Sparks E, Solaro RJ, Shah AM. Essential role of troponin I in the positive inotropic response to isoprenaline in mouse hearts contracting auxotonically. *J Physiol* 2004;**556**:835–847.

41. Marston SB, de Tombe PP. Troponin phosphorylation and myofilament Ca^{2+}-sensitivity in heart failure: increased or decreased? *J Mol Cell Cardiol* 2008;**45**:603–607.

42. Huang X, Pi Y, Lee KJ, Henkel AS, Gregg RG, Powers PA, Walker JW. Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. *Circ Res* 1999;**84**: 1–8.

43. Engelhardt S, Boknik P, Keller U, Neumann J, Lohse MJ, Hein L. Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta1-adrenergic receptor. *FASEB J* 2001;**15**:2718–2720.

44. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. *J Clin Invest* 2013;**123**:46–52.

45. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. *Circulation* 2004;**109**:1154–1160.

46. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW II, MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. *J Clin Invest* 2003;**111**:869–876.

47. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. *Nature* 1997;**390**:88–91.

48. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. *Circulation* 1999;**100**:2210–2212.

49. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. *Circulation* 2004;**110**:1083–1090.

50. Ahmet I, Lakatta EG, Talan MI. Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. *Heart Fail Rev* 2005;**10**:289–296.

51. Peter PS, Brady JE, Yan L, Chen W, Engelhardt S, Wang Y, Sadoshima J, Vatner SF, Vatner DE. Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. *J Clin Invest* 2007;**117**:1335–1343.

52. Communal C, Colucci WS, Singh K. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for G_i-dependent activation. *J Biol Chem* 2000;**275**:19395–19400.

53. Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, Balke CW, Lakatta EG, Cheng H. Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)—but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. *Circulation* 2003;**108**:1633–1639.

54. Reinartz MT, Kalble S, Littmann T, Ozawa T, Dove S, Kaever V, Wainer IW, Seifert R. Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the beta2-adrenoceptor. *Naunyn Schmiedebergs Arch Pharmacol* 2015;**388**: 51–65.

55. Kaur K, Parra S, Chen R, Charbeneau RA, Wade SM, Jay PY, Neubig RR. $Galpha_{i2}$ signaling: friend or foe in cardiac injury and heart failure? *Naunyn Schmiedebergs Arch Pharmacol* 2012;**385**:443–453.

56. Hussain RI, Aronsen JM, Afzal F, Sjaastad I, Osnes JB, Skomedal T, Levy FO, Krobert KA. The functional activity of inhibitory G protein (G(i)) is not increased in failing heart ventricle. *J Mol Cell Cardiol* 2013;**56**:129–138.